Scarica l'app Stockscreener
45.00
2.30%
-1.06
Pre-mercato:
45.92
0.92
+2.04%
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Uniqure NV (QURE) Stock News Today - TradingKey
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: Exploring A 53.35% Potential Upside In Gene Therapy - DirectorsTalk Interviews
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
QURE|Uniqure NV|Price:44.206|Chg%:-0.034 - TradingKey
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
Weekly Recap: AMT-130 readout and Wells Fargo raises QURE target to $75 - TradingView
uniQure N.V. (QURE) Stock Analysis: Assessing Upside Potential and Analyst Confidence in Biotech Innovator - DirectorsTalk Interviews
RBC Capital Sticks to Their Buy Rating for uniQure (QURE) - The Globe and Mail
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - Yahoo Finance
Uniqure NV earnings missed by $0.38, revenue topped estimates - Investing.com Nigeria
uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary - TradingView
UniQure: Q2 Earnings Snapshot - 10tv.com
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update - GlobeNewswire
uniQure stock upgraded by Wolfe Research on Huntington’s therapy outlook - Investing.com
uniQure earnings in focus as AMT-130 gene therapy BLA looms By Investing.com - Investing.com Australia
uniQure earnings in focus as AMT-130 gene therapy BLA looms - Investing.com
Uniqure NV (QURE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Uniqure NV (QURE) Income Statement - TradingKey
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Uniqure NV (QURE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kalehua Capital Management LLC Makes New Investment in uniQure N.V. $QURE - MarketBeat
Orbimed Advisors LLC Has $34.93 Million Holdings in uniQure N.V. $QURE - MarketBeat
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Uniqure NV (QURE) Balance Sheet - TradingKey
QURE|Uniqure NV|Price:38.230|Chg%:-0.740 - TradingKey
Uniqure NV (QURE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Uniqure NV (QURE) Cash Flow - TradingKey
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Revenue Breakdown – FWB:UQ1 - TradingView
uniQure (QURE) to Release Earnings on Wednesday - MarketBeat
uniQure N.V. Revenue Breakdown – BIVA:QURE/N - TradingView
Siren L.L.C. Makes New $16.35 Million Investment in uniQure N.V. $QURE - MarketBeat
uniQure N.V. (QURE) Stock Analysis: Exploring a 63.82% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Aberdeen Group plc Reduces Holdings in uniQure NV - GuruFocus
Uniqure NV (QURE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29 - Moomoo
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Militia Capital Management LLC Purchases New Shares in uniQure N.V. $QURE - MarketBeat
uniQure N.V. to announce Q2 2026 financial results on July 29 - scanx.trade
uniQure to Announce Second Quarter 2026 Financial Results - The Manila Times
uniQure sets July 29 webcast after Q2 financial results - Stock Titan
uniQure N.V. $QURE Shares Sold by Jennison Associates LLC - MarketBeat
JPMorgan Chase & Co. Increases Stake in uniQure NV - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $46 - Moomoo
uniQure (QURE) Proxy filing Summary - Quartr
uniQure (NASDAQ:QURE) Shares Pass Above 50 Day Moving AverageTime to Sell? - MarketBeat
Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure - Stock Titan
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold? - MSN
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise - Yahoo Finance
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - The Globe and Mail
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway - Yahoo Finance
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - GuruFocus
UniQure (QURE) now trades above golden cross: Time to buy? - MSN
0.39%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):